MU Deadline: Rosen Law Firm Urges Micron Technology, Inc. (NASDAQ: MU) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK–(BUSINESS WIRE)–Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers... Read more.
US Smart Home Integration, Automation, and Control Market Analysis Report 2024: Focus on Influencing Consumer Purchase Behavior and Preferences – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Smart Home: Integration, Automation, and Control” report has been added to ResearchAndMarkets.com’s offering.... Read more.
RC INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Ready Capital Corporation Investors with Substantial Losses Have Opportunity to Lead the Ready Capital Class Action Lawsuit
SAN DIEGO–(BUSINESS WIRE)–The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Ready Capital Corporation (NYSE:... Read more.
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
— Results presented in AAD late-breaker demonstrate bempikibart’s encouraging improvement on SALT reduction at week 24 and continued effects after dosing... Read more.
LEO Pharma Presents New Late-Breaking Delgocitinib Cream Data For the Third Consecutive Year at AAD 2025
The post hoc analysis investigated treatment responses in a patient subgroup with moderate to severe Chronic Hand Eczema (CHE) treated with delgocitinib cream for... Read more.
Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
– Full data from the Phase 3 TRuE-PN1 study, presented today in a late-breaking oral presentation, showed the study met all primary and key secondary endpoints... Read more.
Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
Significantly more patients treated with Sotyktu achieved ACR and PASI response rates and had greater improvements in patient-reported quality of life compared with... Read more.
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older
Low disease activity was observed after a mean duration of 80 consecutive days off-treatment following success with VTAMA cream, with a mean weekly Peak Pruritus... Read more.
The Trust Crisis: Why Data Governance Will Make or Break Our AI Future
In the rush to embrace artificial intelligence, we’re overlooking a looming crisis that threatens to undermine the entire digital economy: the collapse of... Read more.
Sustainable Power: Solving the energy challenges of AI
Today, many of the macro trends accelerating data centre adoption are being driven by increasingly compute intensive applications. Generative artificial intelligence... Read more.